BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 23130835)

  • 1. Chromatin regulators with tumor suppressor properties and their alterations in human cancers.
    Shu XS; Li L; Tao Q
    Epigenomics; 2012 Oct; 4(5):537-49. PubMed ID: 23130835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.
    Oike T; Ogiwara H; Nakano T; Yokota J; Kohno T
    Jpn J Clin Oncol; 2013 Sep; 43(9):849-55. PubMed ID: 23904343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SWI/SNF complex in cancer.
    Lu C; Allis CD
    Nat Genet; 2017 Jan; 49(2):178-179. PubMed ID: 28138149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells.
    Stirzaker C; Song JZ; Davidson B; Clark SJ
    Cancer Res; 2004 Jun; 64(11):3871-7. PubMed ID: 15172996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic mechanism of rRNA gene silencing: temporal order of NoRC-mediated histone modification, chromatin remodeling, and DNA methylation.
    Santoro R; Grummt I
    Mol Cell Biol; 2005 Apr; 25(7):2539-46. PubMed ID: 15767661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
    Magdinier F; Wolffe AP
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4990-5. PubMed ID: 11309512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving epigenome.
    Weichenhan D; Plass C
    Hum Mol Genet; 2013 Oct; 22(R1):R1-6. PubMed ID: 23900077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetics and cancer: altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation.
    Sansam CG; Roberts CW
    Cell Cycle; 2006 Mar; 5(6):621-4. PubMed ID: 16582616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
    Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
    Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromatin modifiers and tumor suppression.
    Klochendler-Yeivin A; Yaniv M
    Biochim Biophys Acta; 2001 Aug; 1551(1):M1-10. PubMed ID: 11553416
    [No Abstract]   [Full Text] [Related]  

  • 11. [DNA methylation and cancer].
    Yoshikawa H
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):145-9. PubMed ID: 17301518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of expression of the chromatin remodeling gene, SNF2L, selectively leads to DNA damage, growth inhibition, and cancer cell death.
    Ye Y; Xiao Y; Wang W; Wang Q; Yearsley K; Wani AA; Yan Q; Gao JX; Shetuni BS; Barsky SH
    Mol Cancer Res; 2009 Dec; 7(12):1984-99. PubMed ID: 19996304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Roles of Chromatin Remodeling Proteins in Cancer.
    Zhang C; Lu J; Zhang P
    Curr Protein Pept Sci; 2016; 17(5):446-54. PubMed ID: 26796304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recruitment of the nucleolar remodeling complex NoRC establishes ribosomal DNA silencing in chromatin.
    Strohner R; Németh A; Nightingale KP; Grummt I; Becker PB; Längst G
    Mol Cell Biol; 2004 Feb; 24(4):1791-8. PubMed ID: 14749393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development.
    Maleszewska M; Kaminska B
    Future Oncol; 2015 Sep; 11(18):2587-601. PubMed ID: 26289459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromatin dynamics: interplay between remodeling enzymes and histone modifications.
    Swygert SG; Peterson CL
    Biochim Biophys Acta; 2014 Aug; 1839(8):728-36. PubMed ID: 24583555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
    Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
    Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
    Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
    Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications.
    Xiong Y; Dowdy SC; Eberhardt NL; Podratz KC; Jiang SW
    Gynecol Oncol; 2006 Oct; 103(1):321-8. PubMed ID: 16701802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
    Herranz M; Esteller M
    Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.